Abstract

Converting a scientific hypothesis into a market reality while delivering financial rewards to the capital riskers is an uncertain journey for all the protagonists involved.

Early-stage venture capital finances the science needed to identify a lead molecule and develop it further to the proof-of-concept stage. However, the notorious high attrition rate in the discovery phase often curbs its enthusiasm

To increase your chances of scientific success, our approach is to gain a very early in-depth understanding of your molecule as well as of the patient population which most likely benefits from treatment.

Partnering with NUVISAN, a fully-integrated science CRO willing to have skin in the game at your side, the value of your portfolio company will grow efficiently and your return on investment will escalate!

Hosted by Carmen Diez Fernandez, this 45-minute presentation by Dr. Charlotte Kopitz, EVP & Head of Therapeutic Research, and Arnoud Huisman, Chief strategy officer at NUVISAN, will cover:

• De-risking drug development by early translational pharmacolog
• From fit-for-purpose drug candidate to evidence based clinical study design
• Exploring the full indication landscape - and thus market size - of your asset
• Data-driven guidance for decisions on targets, assets and portfolios
• Collaboration Models between CRO´s and VC´s
• Risk-sharing options
• Live Q&A Session